NCT01303380View on ClinicalTrials.gov

Canakinumab in Patients With Active Hyper-IgD Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Mevalonate Kinase Deficiency
Interventions
DRUG

Canakinumab

Trial Locations (3)

28046

Novartis Investigative Site, Madrid

46026

Novartis Investigative Site, Valencia

08950

Novartis Investigative Site, Esplugues de Llobregat

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY